...
首页> 外文期刊>Bioorganic and medicinal chemistry >Synthesis, SAR, and preliminary mechanistic evaluation of novel antiproliferative N 6,5′-bis-ureido- and 5′-carbamoyl- N 6-ureidoadenosine derivatives
【24h】

Synthesis, SAR, and preliminary mechanistic evaluation of novel antiproliferative N 6,5′-bis-ureido- and 5′-carbamoyl- N 6-ureidoadenosine derivatives

机译:新型抗增殖N 6,5'-双-脲基-和5'-氨基甲酰基-N 6-脲基腺苷衍生物的合成,SAR和初步机理评估

获取原文
获取原文并翻译 | 示例

摘要

We have developed efficient methods for the preparation of N 6,5′-bis-ureidoadenosine derivatives and their 5′-carbamoyl-N 6-ureido congeners. Treatment of 5′-azido-5′-deoxy-N 6-(N-alkyl or -arylurea)adenosine derivatives (6a-d) with H 2/Pd-C or Ph 3P/H 2O, followed by N-methyl-p-nitrophenylcarbamate gave N 6,5′-bis- ureido products 7a-d in 49-78% yield. Analogous derivatives in the 5′-carbamoyl-N 6-ureido series were prepared by treatment of 2′,3′-bis-O-TBS-adenosine (11) with N-methyl-p-nitrophenylcarbamate followed by acylation with appropriate isocyanates which gave 13a-d in 45-69% yield. A more versatile route for obtaining potentially vast libraries of compounds from both series was achieved by treatment of 5′-N-methylureido- or 5′-N-methylcarbamoyladenosine derivatives with ethylchlorformate to give N 6-ethoxycarbonyl derivatives (9 and 14) in 55-63% yields, respectively. Simple heating of 9 or 14 in the presence of primary alkyl- or arylamines gave the corresponding N 6,5′-bis-ureido- or 5′-carbamoyl-N 6-ureidoadenosine derivatives in good yields (33-72% and 39-83%; 10a-e and 15a-e, respectively). Significant antiproliferative activities (IC 50 ≈ 4-10 μg/mL) were observed for a majority of the N 6,5′-bis-ureido derivatives, whereas the 5′-carbamoyl-N 6-ureido derivatives were generally less active (IC 50 100 μg/mL). A 2′,3′-O-desilylated derivative (5′-amino-5′-deoxy-5′-N-methylureido-N 6-(N- phenylcarbamoyl)adenosine, 16) was shown to inhibit binding of 16 of 441 protein kinases to immobilized ATP-binding site ligands by 30-40% in a competitive binding assay at 10 μM. Compound 16 was also shown to bind to bone morphogenetic protein receptor 1b (BMPR1b) with a Kd = 11.5 ± 0.7 μM.
机译:我们已经开发了制备N 6,5'-双-脲基腺苷衍生物及其5'-氨基甲酰基-N 6-脲基同源物的有效方法。用H 2 / Pd-C或Ph 3P / H 2O,然后用N-甲基-N-处理5'-叠氮基5'-脱氧-N 6-(N-烷基或-芳基脲)腺苷衍生物(6a-d)对硝基苯基氨基甲酸酯得到N 6,5'-双-脲基产物7a-d,产率为49-78%。通过用N-甲基-对-硝基苯基氨基甲酸酯处理2',3'-双-O-TBS-腺苷(11),然后用适当的异氰酸酯酰化,制得5'-氨基甲酰基-N 6-脲基系列的类似衍生物。以45-69%的收率得到13a-d。通过用氯甲酸乙酯处理5'-N-甲基脲基或5'-N-甲基氨基甲酰腺苷衍生物,在55中得到N 6-乙氧羰基衍生物(9和14),从而获得了一种从这两个系列中获取潜在化合物库的更广泛途径。产率分别为-63%。在伯烷基胺或芳基胺的存在下简单加热9或14,可得到相应的N 6,5'-双脲基-或5'-氨基甲酰基-N 6-脲基腺苷衍生物,收率很高(33-72%和39- 83%;分别为10a-e和15a-e)。对于大多数N 6,5'-双-脲基衍生物,观察到了显着的抗增殖活性(IC 50≈4-10μg/ mL),而5'-氨基甲酰基-N 6-脲基衍生物通常活性较低(IC 50> 100μg/ mL)。已显示2',3'-O-去甲硅烷基化衍生物(5'-氨基-5'-脱氧-5'-N-甲基脲基-N 6-(N-苯基氨基甲酰基)腺苷16)抑制441中的16结合蛋白激酶在10μM的竞争性结合测定中将固定的ATP结合位点配体固定30-40%。还显示了化合物16以Kd = 11.5±0.7μM结合骨形态发生蛋白受体1b(BMPR1b)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号